NVE Corporation NVEC
Set alert
As of Nov 2, 1:57 PM ET
- YTD
- +30.51%
- 1 year
- +12.14%
- Open
- 77.90
- Prev close
- 76.58
- Mkt cap
- 376.34M
- Vol
- 46.73K
- Avg vol
- 128.54K
- EPS
- 3.69
- P/E
- 21.05
- Div yield
- 4.88%
More statistics
- Low
- 77.19
- High
- 80.31
- Forward P/E
- 28.59
- Beta
- 1.13
- Short ratio
- 5.61
- Inst. own
- 69.61%
- Dividend
- 4.00
- Ex-div date
- Nov 3, 2024
- Earnings
- Jan 15, 2025
- 50-d avg
- 78.00
- 200-d avg
- 79.04
- 1y target
- 0.00
1Y chart
Events in this range
- Nov 3, 2025Dividend: 1
- Feb 2, 2026Dividend: 1
- May 18, 2026Dividend: 1
- Aug 3, 2026Dividend: 1
- Nov 2, 2026Dividend: 1
Signals (61)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Jul 23, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 23, 2026 | 3 months ago |
| RSI: Overbought | Jul 23, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 24, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 17, 2026 | 4 months ago |
| RSI: Overbought | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| RSI: Overbought | May 11, 2026 | 5 months ago |
| MACD: Buy Signal | May 1, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| RSI: Overbought | Apr 9, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 2, 2026 | 7 months ago |
| SMA: Bullish | Apr 1, 2026 | 7 months ago |
| SMA: Bullish | Apr 1, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 13, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 11, 2026 | 7 months ago |
| SMA: Bullish | Mar 10, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 6, 2026 | 8 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| SMA: Bullish | Feb 24, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 24, 2026 | 8 months ago |
| SMA: Bearish | Feb 12, 2026 | 8 months ago |
| SMA: Bullish | Feb 11, 2026 | 8 months ago |
| SMA: Bearish | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Feb 2, 2026 | 9 months ago |
| RSI: Overbought | Jan 22, 2026 | 9 months ago |
| SMA: Bullish | Jan 16, 2026 | 9 months ago |
| SMA: Bullish | Jan 14, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 9, 2026 | 9 months ago |
| SMA: Bearish | Dec 22, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 19, 2025 | 10 months ago |
| RSI: Overbought | Dec 10, 2025 | 10 months ago |
| SMA: Bullish | Dec 4, 2025 | 11 months ago |
| SMA: Bullish | Dec 4, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| RSI: Oversold | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
Discussion (2)
Sign in to join the discussion
$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
What makes the div secure